FDA Approves Enfortumab Vedotin Pembrolizumab for Bladder Cancer
Okay, here’s the extracted list of references, formatted for better readability. I’ve also included the URLs where available:
- Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) sBLA granted FDA priority review for treatment of certain patients with muscle-invasive bladder cancer. News release. Astellas. October 22, 2025. Accessed November 11, 2025.
- Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) considerably improved event-free and overall survival and pathologic complete response rate for certain patients with muscle-invasive bladder cancer when given before and after surgery. News release. Merck. August 12, 2025. Accessed November 11, 2025.
important Note: The dates (October 22, 2025, August 12, 2025, November 11, 2025) appear to be in the future as of today, November 15, 2023. This suggests the text is a draft or a preview of information to be released later.